CRO

Reaction Biology and Vyant Bio Announce Closing of Definitive Agreement to Acquire U.S. Operations of Vyant Bio, Inc. Subsidiary

Retrieved on: 
Thursday, November 3, 2022
Syngenic, Research, Science, Therapy, LLC, Time, PTY, Reaction, GLOBE, Method, Biomarker, White & Case, Nasdaq, LLP, Artificial intelligence, Machine learning, Decision-making, CNS, Chief executive officer, Pharmacology, White, Toxicology, Pathology, Drug development, Acquisition, Goal, Rett syndrome, Patient, Neurodegeneration, Cancer, CRO, Drug discovery, Solution, Fine chemical, Pharmaceutical industry

MALVERN, PA and CHERRY HILL, NJ, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Reaction Biology Corporation (“Reaction”), an industry-leading provider of drug discovery services, and Vyant Bio, Inc. (“Vyant Bio”) (Nasdaq: VYNT), an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders, today announced that the companies have closed on a definitive agreement for Reaction to acquire Vyant Bio’s subsidiary vivoPharm LLC, located in Hershey, Pennsylvania.

Key Points: 
  • Reaction will retain U.S. personnel from the acquired operations to establish its Hershey, Pennsylvania presence, which includes in vitro and in vivo capabilities.
  • After these closing adjustments were reflected, $5.5 million was paid at closing.
  • Colliers Securities LLC and Lake Street Capital Markets LLC acted as financial advisors to Vyant Bio in the transaction.
  • Vyant Bio, Inc. (Vyant Bio or the Company) (Nasdaq:VYNT), is an innovative biotechnology company focused on identifying unique biological targets and novel and repurposed therapeutics.

Global Clinical Trials Outsourcing Market Report 2022: Lower Costs, Shorter Turnaround Times, and Better Results Drive Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, November 4, 2022
Professional Services, Health, Clinical Trials, Pharmaceutical, Outsourcing Business, Biotechnology, API, Bronchitis, Workflow, Growth, Time, Investment, Merck, Industry, Degenerative disease, Solution, Population, Tablet, TB, COVID-19, Revenue, ICON, Merck & Co., Clinical trial, Drug resistance, Environment, Prevalence, USD, Respiratory system, Biostatistics, CRO, Chemistry (relationship), Efficiency, Fine chemical, Pharmaceutical industry, LLC, IQVIA

The global clinical trials outsourcing market size is expected to reach USD 67.62 billion by 2030, according to a new study.

Key Points: 
  • The global clinical trials outsourcing market size is expected to reach USD 67.62 billion by 2030, according to a new study.
  • Clinical trial outsourcing includes advantages such as lower costs, shorter turnaround times, and better results.
  • These factors contribute to the market need for clinical trials outsourcing on a global scale.
  • The publisher has segmented the clinical trials outsourcing market report based on workflow, therapeutic area, end-use, and region:
    Clinical Trials Outsourcing, Workflow Outlook (Revenue - USD Billion, 2018 - 2030)

Preclinical CRO Global Market Report 2022: Rising Number of Drugs in Preclinical Trials Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, November 4, 2022
Pharmaceutical, Science, Health, Research, Competitive landscape, CRO, CAGR, Fine chemical

The "Preclinical CRO Market: Global Market Size, Forecast, Insights, and Competitive Landscape" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Preclinical CRO Market: Global Market Size, Forecast, Insights, and Competitive Landscape" report has been added to ResearchAndMarkets.com's offering.
  • The global preclinical CRO market is expected to grow at a CAGR of around 10.4% during 2022-2028.
  • This report on global preclinical CRO market report provides holistic understanding of the market along with market sizing, forecast, drivers, challenges, and competitive landscape.
  • The report presents a clear picture of the global preclinical CRO market by segmenting the market based on service, end-use, and region.

Emplifi bolsters its leadership team with appointment of new Chief Revenue Officer and Chief Growth Officer

Retrieved on: 
Thursday, November 3, 2022
Technology, Publishing, Public Relations, Investor Relations, Marketing, Advertising, Communications, Software, Social Media, Search Engine Marketing, Blogging, Lithium, CGO, Smith, Growth, Solution, McDonald's, Macdonald, Marketing, Commerce, Accenture, Adobe, Ford Motor Company, Delta Air Lines, SafeBreach, UGC, Salsify, CX, Acquisition, Ecosystem, Khoros, LLC, CRO, Microsoft, Management, Sitecore, Emplify

Emplifi , the leading unified customer experience platform, today announced two executive appointments, with Ken Smith joining as Chief Revenue Officer and Vijayanta Gupta as Chief Growth Officer, reporting directly to Emplifi CEO Mark Zablan.

Key Points: 
  • Emplifi , the leading unified customer experience platform, today announced two executive appointments, with Ken Smith joining as Chief Revenue Officer and Vijayanta Gupta as Chief Growth Officer, reporting directly to Emplifi CEO Mark Zablan.
  • Im excited to add both Ken and Vijayanta to Emplifis leadership team.
  • Between them, they bring extensive experience building and scaling revenue at high-growth software companies, said Emplifi CEO Mark Zablan.
  • Emplifi is the leading unified CX platform that brings marketing, commerce, and care together to help businesses close the customer experience gap.

Christian and Timbers Recruits CFO for Desktop Metal

Retrieved on: 
Thursday, November 3, 2022
Machinery, Professional Services, Hardware, Machine Tools, Metalworking & Metallurgy, Electronic Design Automation, Technology, Semiconductor, Other Manufacturing, Engineering, Human Resources, Consulting, Manufacturing, CFO, Silicon, Big Tech, Growth, Multimedia, Unicorn, Industry, NYSE, Biogen, SecurityScorecard, Knowledge, FP, Naval EOD Technology Division, Cisco Systems, Headhunter, Desktop Metal, Analog Devices, Lumber, CFOS, Cellink, Adobe, Capital, Apple, Global Operations, Technology, CNBC, HP, CRO, DM, 3D printing, Management, Upwork

View the full release here: https://www.businesswire.com/news/home/20221103005204/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221103005204/en/
    Christian and Timbers Recruits CFO for Desktop Metal (Photo: Business Wire)
    Desktop Metal Inc. (NYSE: DM) is a global leader in additive manufacturing technologies for mass production, powering some of the best known manufacturers in the world.
  • In his new role, Jason will be focused on leading Desktop Metal s next-generation financial platform to ensure the companys continued profitable hyper-growth.
  • Jason is a remarkable contemporary CFO with in-depth knowledge and experience driving highly efficient rapid growth, according to Jeff Christian , Christian & Timbers CEO.
  • Jeff Christian , author of " The Headhunters Edge " and founder of Christian & Timbers , has been named four years on the Forbes Midas List.

Netrix Global Appoints CFO and CRO on the Heels of Five Recent Acquisitions

Retrieved on: 
Thursday, November 3, 2022
Software, Networks, Internet, Professional Services, Data Management, Technology, Small Business, Security, Other Professional Services, Other Technology, Consulting, Telecommunications, Cloud, CFO, Workforce, Growth, Datto, History, Avaya, LRN, MSSP, CEO, MSA, Poly, Global, Palo Alto Networks, Dell, MSP, OVHcloud, RBC Capital Markets, Technology, Budget, CRO, Solution, Management, Risk management, Gel, Facebook, Colla netrix

Dean Gels has been appointed Chief Financial Officer (CFO), and Josh Hoffman joins as Chief Revenue Officer (CRO).

Key Points: 
  • Dean Gels has been appointed Chief Financial Officer (CFO), and Josh Hoffman joins as Chief Revenue Officer (CRO).
  • These two leaders are poised to build on the rapid growth momentum following the recent acquisitions of five companies , which Netrix has successfully integrated.
  • They each bring more than 20 years of technology leadership experience and proven results in scaling businesses across global markets.
  • For more information, please visit www.netrixglobal.com and follow Netrix Global on LinkedIn , Facebook , and Twitter .

Precision for Medicine Accelerating Precision Oncology with Next Generation Screening to Support New Cancer Diagnostics

Retrieved on: 
Thursday, November 3, 2022
Senior, Colon, Precision, Clinical trial, Association, Ion semiconductor sequencing, Prevalence, Medicine, Gene, Neoplasm, Association for Molecular Pathology v. Myriad Genetics, Inc., Therapy, Thermo Fisher Scientific, DNA sequencing, Doctor of Philosophy, Tissue, Mutation, Method, Patient, Cancer, Prostate, CRO, CNV, Biomarker, Breast, Melanoma, Precision medicine, Lung, NGS, Database, Medical imaging, Pharmaceutical industry

Collaborating with Thermo Fisher, Precision for Medicine performed a mass screening of samples from Precision's extensive biorepository for key mutations across 11 cancer indications, including lung, breast, colon, prostate, melanoma, thyroid, bladder and others.

Key Points: 
  • Collaborating with Thermo Fisher, Precision for Medicine performed a mass screening of samples from Precision's extensive biorepository for key mutations across 11 cancer indications, including lung, breast, colon, prostate, melanoma, thyroid, bladder and others.
  • Accelerating the validation and regulatory approval process will ultimately lead to faster development of personalized (targeted) therapeutics and diagnostics for patients."
  • Ongoing work includes using these tumors to support cross-site validation of novel diagnostics for regulatory approval."
  • Precision for Medicine is part of Precision Medicine Group with over 3000 people in 40 locations in the U.S., Canada, and Europe.

GuardKnox Expands Executive Team, Names New CRO and CTO

Retrieved on: 
Thursday, November 3, 2022
VP, Growth, System, Travel, Virgin Hyperloop, Siemens, CEO, Marketing, Transport, Industry, Technology, Goldberg, Doctor of Philosophy, Name, CRO, Carrot, Automotive industry, DXC Technology, Green Hills Software, Partnership, Women in the automotive industry, Imperial College London, EU, NXP, Management, Jillian, Software, Knut

RAMLA, Israel and MUNICH, Nov. 3, 2022 /PRNewswire/ -- GuardKnox, a leading AutoTech company enabling the next generation of driver-centric mobility, announced today the promotion of two executives to its leadership team. Jillian Goldberg, formerly VP of Marketing and Investor Relations, will be elevated to Chief Revenue & Investor Officer (CRO), and Dr. Knut Sauer, formerly GuardKnox's EU Managing Director, to Group Chief Technology Officer (CTO). As industry mavens, Sauer and Goldberg will be instrumental to propelling GuardKnox's mission to offer drivers a customizable, and personalized vehicle experience. 

Key Points: 
  • "Jillian's tenacity, work ethic, and strong business capabilities are invaluable to GuardKnox, and I am so proud to be working side-by-side with her.
  • Jillian is an executive board member at the Nevo Network, a professional development organization for new immigrants in tech.
  • As CRO, Goldberg will report to the CEO, and be focal to marketing, business & partnership development, and investor relations.
  • Founded in 2016, GuardKnox is based in Israel, with subsidiary locations in Munich, Germany, and Detroit, Michigan.

GuardKnox Expands Executive Team, Names New CRO and CTO

Retrieved on: 
Thursday, November 3, 2022
VP, Growth, System, Travel, Virgin Hyperloop, Siemens, CEO, Marketing, Transport, Industry, Technology, Goldberg, Doctor of Philosophy, Name, CRO, Carrot, Automotive industry, DXC Technology, Green Hills Software, Partnership, Women in the automotive industry, Imperial College London, EU, NXP, Management, Jillian, Software, Knut

RAMLA, Israel and MUNICH, Nov. 3, 2022 /PRNewswire/ -- GuardKnox, a leading AutoTech company enabling the next generation of driver-centric mobility, announced today the promotion of two executives to its leadership team. Jillian Goldberg, formerly VP of Marketing and Investor Relations, will be elevated to Chief Revenue & Investor Officer (CRO), and Dr. Knut Sauer, formerly GuardKnox's EU Managing Director, to Group Chief Technology Officer (CTO). As industry mavens, Sauer and Goldberg will be instrumental to propelling GuardKnox's mission to offer drivers a customizable, and personalized vehicle experience. 

Key Points: 
  • "Jillian's tenacity, work ethic, and strong business capabilities are invaluable to GuardKnox, and I am so proud to be working side-by-side with her.
  • Jillian is an executive board member at the Nevo Network, a professional development organization for new immigrants in tech.
  • As CRO, Goldberg will report to the CEO, and be focal to marketing, business & partnership development, and investor relations.
  • Founded in 2016, GuardKnox is based in Israel, with subsidiary locations in Munich, Germany, and Detroit, Michigan.

Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza

Retrieved on: 
Tuesday, November 1, 2022
Annual report, Nobel Prize, CRO, Cocrystal, SEC, GLOBE, Nasdaq, Norovirus, COCP, Patent, CAGR, Private Securities Litigation Reform Act, Union, Patient, Severe acute respiratory syndrome coronavirus 2, Medicines and Healthcare products Regulatory Agency, Risk, Vaccine, Pharmaceutical industry, Favipiravir

Cocrystal recently announced the completion of enrollment in a Phase 1 study with CC-42344 for the treatment of pandemic and seasonal influenza A, with topline study results expected later this year.

Key Points: 
  • Cocrystal recently announced the completion of enrollment in a Phase 1 study with CC-42344 for the treatment of pandemic and seasonal influenza A, with topline study results expected later this year.
  • The granting of this patent is an important step in our efforts to expand protection of our novel, best-in-class antiviral candidates both in the U.S. and internationally.
  • CC-42344 is an oral PB2 inhibitor discovered using Cocrystals proprietary structure-based drug discovery platform technology.
  • CC-42344 targets the influenza polymerase, an essential replication enzyme with several highly essential regions common to multiple influenza strains.